tetano
Editor, Senior Moderator
J Clin Med
. 2023 Feb 20;12(4):1672.
doi: 10.3390/jcm12041672.
COVID-19-Related Neuropathic Pain: A Systematic Review and Meta-Analysis
Laura Dawn Williams[SUP] 1 [/SUP], Panagiotis Zis[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
Introduction: SARS-CoV-2, responsible for the coronavirus disease (COVID-19) pandemic, may impact other systems apart from the respiratory system, including the nervous system. In this systematic review, we aimed to establish the prevalence and determinants of neuropathic pain amongst COVID-19-infected individuals.
Methodology: A literature search in the PubMed database was performed and 11 papers were eligible for inclusion in this systematic review and meta-analysis.
Results: The pooled prevalence of COVID-19-related neuropathic pain was 6.7% (95% CI: 4.7-9.5%) for hospitalised patients during the acute phase and 34.3% (95% CI: 14.3-62%) for long COVID patients. The identified risk factors for COVID-19-related neuropathic pain development included depression, COVID-19 severity and azithromycin use.
Conclusions: Neuropathic pain is a very common symptom in long COVID, indicating the urgency for further research in this direction.
Keywords: COVID-19; long COVID; neuropathic pain.
. 2023 Feb 20;12(4):1672.
doi: 10.3390/jcm12041672.
COVID-19-Related Neuropathic Pain: A Systematic Review and Meta-Analysis
Laura Dawn Williams[SUP] 1 [/SUP], Panagiotis Zis[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 36836207
- PMCID: PMC9966617
- DOI: 10.3390/jcm12041672
Abstract
Introduction: SARS-CoV-2, responsible for the coronavirus disease (COVID-19) pandemic, may impact other systems apart from the respiratory system, including the nervous system. In this systematic review, we aimed to establish the prevalence and determinants of neuropathic pain amongst COVID-19-infected individuals.
Methodology: A literature search in the PubMed database was performed and 11 papers were eligible for inclusion in this systematic review and meta-analysis.
Results: The pooled prevalence of COVID-19-related neuropathic pain was 6.7% (95% CI: 4.7-9.5%) for hospitalised patients during the acute phase and 34.3% (95% CI: 14.3-62%) for long COVID patients. The identified risk factors for COVID-19-related neuropathic pain development included depression, COVID-19 severity and azithromycin use.
Conclusions: Neuropathic pain is a very common symptom in long COVID, indicating the urgency for further research in this direction.
Keywords: COVID-19; long COVID; neuropathic pain.